| Literature DB >> 25727152 |
Hassan Lemjabbar-Alaoui1, Andrew McKinney2, Yi-Wei Yang1, Vy M Tran2, Joanna J Phillips3.
Abstract
Alterations in glycosylation are common in cancer and are thought to contribute to disease. Lung cancer and primary malignant brain cancer, most commonly glioblastoma, are genetically heterogeneous diseases with extremely poor prognoses. In this review, we summarize the data demonstrating that glycosylation is altered in lung and brain cancer. We then use specific examples to highlight the diverse roles of glycosylation in these two deadly diseases and illustrate shared mechanisms of oncogenesis. In addition to alterations in glycoconjugate biosynthesis, we also discuss mechanisms of postsynthetic glycan modification in cancer. We suggest that alterations in glycosylation in lung and brain cancer provide novel tumor biomarkers and therapeutic targets.Entities:
Keywords: Biomarker; GBM; Glioblastoma; Glycosylation in cancer; HPSE; HSPG; Lung cancer; SULF
Mesh:
Substances:
Year: 2015 PMID: 25727152 PMCID: PMC6080207 DOI: 10.1016/bs.acr.2014.11.007
Source DB: PubMed Journal: Adv Cancer Res ISSN: 0065-230X Impact factor: 6.242